Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Think Positive: Clovis Confident Of CHMP Okay For Rubraca

Executive Summary

The US biotech expects to finally get its PARP inhibitor for ovarian cancer onto the European market in the next few months to compete with rivals AstraZeneca and Tesaro after the CHMP "communicated a positive trend vote" ahead of an opinion being issued next month.

Advertisement

Related Content

Fresh EU Okay For Rubraca Boosts Clovis
Clovis Confident, Portola Not: CHMP Decides On EU Marketing Applications
Bumper Number Of 'Oral Explanations' Due At CHMP Meeting
Lynparza Gets First Mover Advantage In BRCA-Positive Breast Cancer
EU Approval In Sight For New ATMP, Products For XLH And Diabetes, And 2nd Biosimilar Herceptin
Tesaro Shakes Up EU PARP Market With Zejula Launches
The PARP Combo Race Is On: Clovis And Bristol Partner On Rubraca

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100447

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel